<DOC>
	<DOCNO>NCT02954081</DOCNO>
	<brief_summary>Patient treatment preference treatment satisfaction physicians patient compare fumaric acid ester therapy subsequent apremilast treatment</brief_summary>
	<brief_title>APremilast After FumaRic Acid Ester Treatment</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Adult patient ≥18 year Moderate severe plaquetype psoriasis accord SmPC Phase I : Patients include started systemic fumaric acid ester ( e.g . Fumaderm initial® ) treatment moderatetosevere psoriasis vulgaris . Patients initiated fumaric acid ester follow maximum 24 week phase I . Patients continue fumaric acid ester beyond 24 week switch therapy apremilast end 24week phase I period longer follow . Phase II : Patients switch apremilast end 24week phase I period include phase II follow additional 32 week . Written inform consent Prior treatment biologics According SmPC Participation another clinical trial ( parallel inclusion National psoriasis registry PsoBest allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>